A 32-year-old Indian woman with newly diagnosed hypertension is started on enalapril 10 mg daily. After 2 weeks, she develops severe angioedema of the lips and tongue requiring emergency management. Genetic testing reveals she carries a loss-of-function variant in the ACE gene (rs4646994 insertion/deletion polymorphism). Her brother, who also carries the same variant, tolerated enalapril well without angioedema. Which pharmacogenomic principle BEST explains the variable clinical response to enalapril in this family?

## Pharmacogenomic Basis of Variable ACE Inhibitor Response ### Clinical Context ACE inhibitor–induced angioedema is a rare but life-threatening adverse effect (incidence 0.1–0.5%). The ACE gene insertion/deletion polymorphism (rs4646994) influences circulating ACE levels and bradykinin degradation. However, the key pharmacogenomic question here is: **why does the same genetic variant produce angioedema in one sibling but not the other?** ### The Correct Principle: Penetrance and Variable Expressivity **Key Point:** When a genetic variant is present in multiple family members but produces different clinical phenotypes, the pharmacogenomic principles of **penetrance** (the proportion of individuals with a genotype who express the associated phenotype) and **variable expressivity** (the degree to which a phenotype is expressed among those who do express it) are the most appropriate explanatory framework. - The proband carries the ACE variant → develops severe angioedema (full expressivity) - Her brother carries the **same** ACE variant → no angioedema (reduced penetrance) This is a textbook illustration of how a single pharmacogenomic variant does not deterministically produce a phenotype in every carrier — environmental factors, modifier loci, and stochastic variation all contribute to incomplete penetrance and variable expressivity. ### Why Not Gene-Gene Interaction (Option D)? While BDKRB2 polymorphisms have been studied in the context of ACE inhibitor angioedema in research settings, **gene-gene interaction (epistasis) as the primary mechanistic explanation is not established in standard pharmacology textbooks** (KD Tripathi, Goodman & Gilman) used for NEET PG. The question stem does not provide BDKRB2 genotype data for either sibling, making this an inference beyond the given information. The principle that **best explains** variable response to the same variant within a family — as asked — is penetrance and variable expressivity. ### Why Not the Other Options? | Option | Why It Doesn't Fit | |--------|-------------------| | **Epigenetic silencing (A)** | Epigenetic changes are acquired and tissue-specific; they cannot reliably explain stable, heritable differences in drug response between siblings sharing the same germline variant. | | **BDKRB2 pharmacodynamic polymorphisms alone (C)** | This option attributes the variability solely to BDKRB2 receptor differences, without invoking the interaction with the ACE variant described in the stem. It is also not supported as a standalone explanation in standard NEET PG texts. | | **Gene-gene interaction (D)** | Plausible mechanistically but requires BDKRB2 genotype data not provided in the stem; this is research-level knowledge not established in standard pharmacology references for NEET PG. | ### High-Yield Summary **Clinical Pearl:** Penetrance and variable expressivity are fundamental pharmacogenomic concepts explaining why carriers of the same pharmacogenomic variant may or may not experience a drug adverse effect. This is the most textbook-supported and exam-relevant principle for this scenario. - **Penetrance**: Not all ACE variant carriers develop angioedema - **Variable expressivity**: Among those who do, severity differs - **Implication**: Genetic testing alone cannot guarantee prediction of adverse drug reactions [cite: KD Tripathi Essentials of Medical Pharmacology 8e, Chapter 10 — Pharmacogenomics; Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13e]